Defective high-affinity thiamine transporter leads to cell death in thiamine-responsive megaloblastic anemia syndrome fibroblasts
- PMID: 10074490
- PMCID: PMC408117
- DOI: 10.1172/JCI3895
Defective high-affinity thiamine transporter leads to cell death in thiamine-responsive megaloblastic anemia syndrome fibroblasts
Abstract
We have investigated the cellular pathology of the syndrome called thiamine-responsive megaloblastic anemia (TRMA) with diabetes and deafness. Cultured diploid fibroblasts were grown in thiamine-free medium and dialyzed serum. Normal fibroblasts survived indefinitely without supplemental thiamine, whereas patient cells died in 5-14 days (mean 9.5 days), and heterozygous cells survived for more than 30 days. TRMA fibroblasts were rescued from death with 10-30 nM thiamine (in the range of normal plasma thiamine concentrations). Positive terminal deoxynucleotide transferase-mediated dUTP nick end-labeling (TUNEL) staining suggested that cell death was due to apoptosis. We assessed cellular uptake of [3H]thiamine at submicromolar concentrations. Normal fibroblasts exhibited saturable, high-affinity thiamine uptake (Km 400-550 nM; Vmax 11 pmol/min/10(6) cells) in addition to a low-affinity unsaturable component. Mutant cells lacked detectable high-affinity uptake. At 30 nM thiamine, the rate of uptake of thiamine by TRMA fibroblasts was 10-fold less than that of wild-type, and cells from obligate heterozygotes had an intermediate phenotype. Transfection of TRMA fibroblasts with the yeast thiamine transporter gene THI10 prevented cell death when cells were grown in the absence of supplemental thiamine. We therefore propose that the primary abnormality in TRMA is absence of a high-affinity thiamine transporter and that low intracellular thiamine concentrations in the mutant cells cause biochemical abnormalities that lead to apoptotic cell death.
Figures





Similar articles
-
The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter.Nat Genet. 1999 Jul;22(3):305-8. doi: 10.1038/10379. Nat Genet. 1999. PMID: 10391222
-
Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA).Blood. 2003 Nov 15;102(10):3556-61. doi: 10.1182/blood-2003-05-1537. Epub 2003 Jul 31. Blood. 2003. PMID: 12893755
-
A novel mutation in the SLC19A2 gene in a Tunisian family with thiamine-responsive megaloblastic anaemia, diabetes and deafness syndrome.Br J Haematol. 2001 May;113(2):508-13. doi: 10.1046/j.1365-2141.2001.02774.x. Br J Haematol. 2001. PMID: 11380424
-
Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport.Blood Cells Mol Dis. 2001 Jan-Feb;27(1):135-8. doi: 10.1006/bcmd.2000.0356. Blood Cells Mol Dis. 2001. PMID: 11358373 Review.
-
Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia.Pediatr Diabetes. 2012 Jun;13(4):314-21. doi: 10.1111/j.1399-5448.2012.00855.x. Epub 2012 Feb 27. Pediatr Diabetes. 2012. PMID: 22369132 Review.
Cited by
-
A novel homozygous SLC19A2 mutation in a Portuguese patient with diabetes mellitus and thiamine-responsive megaloblastic anaemia.Int J Pediatr Endocrinol. 2015;2015(1):6. doi: 10.1186/s13633-015-0002-6. Epub 2015 Apr 15. Int J Pediatr Endocrinol. 2015. PMID: 25878670 Free PMC article.
-
Glucose stimulates protein modification by O-linked GlcNAc in pancreatic beta cells: linkage of O-linked GlcNAc to beta cell death.Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2820-5. doi: 10.1073/pnas.97.6.2820. Proc Natl Acad Sci U S A. 2000. PMID: 10717000 Free PMC article.
-
Vitamin B1 (thiamine) uptake by human retinal pigment epithelial (ARPE-19) cells: mechanism and regulation.J Physiol. 2007 Jul 1;582(Pt 1):73-85. doi: 10.1113/jphysiol.2007.128843. Epub 2007 Apr 26. J Physiol. 2007. PMID: 17463047 Free PMC article.
-
Ion Transporters, Channelopathies, and Glucose Disorders.Int J Mol Sci. 2019 May 27;20(10):2590. doi: 10.3390/ijms20102590. Int J Mol Sci. 2019. PMID: 31137773 Free PMC article. Review.
-
Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome.Diabetologia. 2018 May;61(5):1027-1036. doi: 10.1007/s00125-018-4554-x. Epub 2018 Feb 15. Diabetologia. 2018. PMID: 29450569 Free PMC article.
References
-
- Rogers LE, Porter FS, Sidbury JBJ. Thiamine-responsive megaloblastic anemia. J Pediatr. 1969;74:494–504. - PubMed
-
- Raz T, et al. Refined mapping of the gene for thiamine-responsive megaloblastic anemia syndrome in a 4 cM region and evidence for genetic homogeneity. Hum Genet. 1998;103:455–461. - PubMed
-
- Rotoli B, Poggi V, De Renzo A, Robledo R. In vitro addition of thiamin does not restore BFU-E growth in thiamin-responsive anemia syndrome. Haematologica. 1986;71:441–443. - PubMed
-
- Poggi V, et al. Thiamin-responsive megaloblastic anaemia: a disorder of thiamin transport? J Inherit Metab Dis. 1984;7:153–154. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases